{"id":873620,"date":"2025-08-08T17:02:55","date_gmt":"2025-08-08T21:02:55","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/edesa-biotech-reports-fiscal-3rd-quarter-2025-results\/"},"modified":"2025-08-08T17:02:55","modified_gmt":"2025-08-08T21:02:55","slug":"edesa-biotech-reports-fiscal-3rd-quarter-2025-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/edesa-biotech-reports-fiscal-3rd-quarter-2025-results\/","title":{"rendered":"Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results"},"content":{"rendered":"
\n

TORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE) — Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and nine months ended June 30, 2025 and provided an update on its business.<\/p>\n

During the quarter, the company advanced manufacturing-related activities to support U.S. regulatory approval of a Phase 2 study of Edesa\u2019s drug candidate EB06 (an anti-CXCL10 monoclonal antibody) in patients with moderate-to-severe nonsegmental vitiligo. Edesa anticipates drug manufacturing data for EB06 to be submitted to the U.S. Food and Drug Administration (FDA) for its investigational new drug (IND) application by the end of calendar 2025 based on the current availability of manufacturing slots at third party service providers.<\/p>\n

\u201cOur manufacturing plans are moving forward, and we\u2019re energized by the opportunity to bring an innovative immunotherapy like EB06 into an area of high unmet need,\u201d said Par Nijhawan, MD, Chief Executive Officer of Edesa Biotech. \u201cWe believe that the favorable safety profile of EB06, and its ability to target the immune system mechanisms impacting both lesional and non-lesional skin, has the potential to make it a preferable option for vitiligo patients \u2013 especially for those with lesions on more than 10% of their body surface area or those patients concerned about the safety risks of other treatments.\u201d<\/p>\n

Edesa’s Chief Financial Officer Peter Weiler reported that financial results for the quarter and fiscal year-to-date were in line with management expectations and continued to reflect the refocusing of company resources to its vitiligo development program. He noted that increased expenditures for Edesa\u2019s EB06 program were offset by decreased expenses for its EB05 drug candidate as the company benefits from the fully funded U.S. government \u201cJust Breathe\u201d study of EB05 and other host-directed therapeutics in a general ARDS patient population. During the quarter, the government announced that the first randomizations for the platform study were completed.<\/p>\n

\u201cWe are channeling our operational efforts into regulatory preparation and drug manufacturing of our EB06 candidate with the goal of being in a position to move rapidly into clinical testing,\u201d Mr. Weiler said.<\/p>\n

\n Financial<\/strong>
\n Results<\/strong>
\n for<\/strong>
\n the<\/strong>
\n Three<\/strong>
\n Months Ended<\/strong>
\n June 30,<\/strong>
\n 2025<\/strong>\n <\/p>\n

Total operating expenses for each of the three months ended June 30, 2025 and June 30, 2024 were $1.9 million:<\/p>\n